NLS Pharmaceutics Ltd NLSP 深 滬
等待開盤 10-28 09:30:00 美东时间
1.24
-0.060
-4.62%
華盛通- 最 高1.36
- 今 開1.29
- 成交量 910.86万股
- 最 低 1.21
- 昨 收 1.30
- 總市值 608.59万
- 52周最高 4.74
- 市盈率 靜 --
- 換手率 185.59%
- 52周最低 1.21
- 委 比 -96.86%
- 總股本 490.80万
- 歷史最高 294.00
- 量 比 5.71
- 振 幅 11.54%
- 歷史最低 1.21
- 每 手 1
- 風險率 0.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NLS Pharmaceutics, Kadimastem Receive Approval To List Common Shares On Nasdaq After Merger Under NewcelX Name, NCEL Ticker
NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE:
10-23 18:04
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem
An update from NLS Pharmaceutics ( ($NLSP) ) is now available. On September 30,...
09-30 19:48
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
09-26 20:10
NLS Pharmaceutics Engages New Accounting Firm After Marcum’s Resignation
NLS Pharmaceutics ( ($NLSP) ) just unveiled an update. On September 17, 2025, N...
09-20 04:28
NLS Pharmaceutics shares are trading lower after the company announced it rescheduled its shareholder meeting to address SEC feedback and provide updated information.
NLS Pharmaceutics shares are trading lower after the company announced it resch...
08-27 00:54
NLS Pharma's Diabetes Treatment Project Gets Fresh Funding Boost From US-Israel Foundation
NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system disorders, today announced that the Israel-U.S. Binational Industrial Research and
07-17 19:02
Why Greenbrier Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Shares of The Greenbrier Companies, Inc. (NYSE: GBX) rose sharply in today's pre-market trading after the company posted stronger-than-expected results for the third quarter. The company posted quarterly earnings of $1.86 per share, beating market estimates of 98 cents per share.
07-02 17:55
NLS Pharmaceutics Gains Shareholder Approval for Strategic Agenda
NLS Pharmaceutics ( ($NLSP) ) just unveiled an update. On June 30, 2025, NLS Ph...
07-02 04:56
NLS Pharmaceutics Extends Merger Agreement with Kadimastem
An announcement from NLS Pharmaceutics ( ($NLSP) ) is now available. On July 1,...
07-02 04:28
NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing
Accumulated proceeds of $3 million including the initial closing held in March 2025 ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Sw...
06-30 19:00
